Concepedia

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis

DoQuyen Huynh, Tristan Boyd, C.J. Etzel, Veronica Cox, Joel Kremer, Philip J. Mease, Arthur Kavanaugh

RMD Open · 2017 · 29 citations · 7 references

DOIFull text

Open access

Abstract

Patients with PsA who achieve LDA may maintain clinical benefit after discontinuation of TNFi therapy.

References

7

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

Laura C. Coates, Anna R. Moverley, Lucy McParland et al. · The Lancet · 2015 · 466 citations · Full text

, , +15

Remission in psoriatic arthritis: is it possible and how can it be predicted?

T. Saber, G Renard, Bernadette Lynch et al. · Arthritis Research & Therapy · 2010 · 87 citations · Full text

Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs

Fabrizio Cantini, Laura Niccoli, Carlotta Nannini et al. · Lara D. Veeken · 2008 · 83 citations · Full text

High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission

Elizabeth Araújo, Stephanie Finzel, Matthias Englbrecht et al. · Annals of the Rheumatic Diseases · 2013 · 62 citations

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Fabrizio Cantini, Niccoli Laura, Cassara et al. · Biologics · 2012 · 48 citations · Full text